Academic Journals Database
Disseminating quality controlled scientific knowledge

Pharmacodynamics of vancomycin in elderly patients aged 75 years or older with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia

Author(s): Mizokami F | Shibasaki M | Yoshizue Y | Noro T | Mizuno T | Furuta K

Journal: Clinical Interventions in Aging
ISSN 1176-9092

Volume: 2013;
Issue: default;
Start page: 1015;
Date: 2013;
Original page

Fumihiro Mizokami,1 Masataka Shibasaki,2 Yasunori Yoshizue,1 Takeshi Noro,1 Tomohiro Mizuno,3 Katsunori Furuta41Department of Pharmacy, 2Department of Respiratory Medicine, National Center for Geriatrics and Gerontology, Obu, 3Department of Analytical Pharmacology, Meijo University Graduate School of Pharmacy, Nagoya, 4Department of Clinical Research and Development, National Center for Geriatrics and Gerontology, Obu, JapanBackground: Methicillin-resistant Staphylococcus aureus (MRSA) infections are associated with significant mortality and health care costs. To improve treatment outcomes for MRSA, a better understanding of the pharmacokinetic/pharmacodynamic parameters of vancomycin is required to develop optimal dosing strategies, particularly in elderly patients (≥75 years of age) with limited renal function. The purpose of this study was to determine whether pharmacokinetic indices for vancomycin are associated with mortality from MRSA hospital-acquired pneumonia in elderly patients.Methods: We conducted a retrospective observational study with 28-day mortality as the primary outcome for 94 patients with MRSA hospital-acquired pneumonia who had been treated with vancomycin from January 2006 through December 2012. Our most recent sampling of MRSA isolates had a minimum inhibitory concentration (MIC) for vancomycin of 1 µg/mL (86%), indicating that the area under the curve (AUC) was equal to the AUC/MIC in these isolates. The primary data from 28-day survivors and nonsurvivors were compared.Results: Among 94 elderly patients, the mean age was 82 (75–99) years. Multivariate analyses revealed that, among the factors examined, only the nonoptimal AUC (450 µg*h/mL) was an independent predictor of 28-day mortality in elderly patients (odds ratio 23.156, 95% confidence interval 6.814–78.687, P < 0.001). We detected a significant difference for increasing nephrotoxicity in nonsurvivors (nine of 32 patients [28%]) compared with survivors (three of 62 patients [4.8%], P = 0.003).Conclusion: This finding indicates that patients with potentially poor renal function are likely to have increased AUC values and a poor prognosis. Consideration of the pharmacokinetics/pharmacodynamics of vancomycin and targeting an AUC/MIC value of 250–450 µg*h/mL may result in improved treatment outcomes for elderly patients with MRSA hospital-acquired pneumonia.Keywords: methicillin-resistant Staphylococcus aureus, elderly patients, vancomycin, pharmacokinetics, pharmacodynamics
RPA Switzerland

RPA Switzerland

Robotic process automation


Tango Jona
Tangokurs Rapperswil-Jona